274 related articles for article (PubMed ID: 17105953)
1. Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics.
Abanades S; Farré M; Segura M; Pichini S; Barral D; Pacifici R; Pellegrini M; Fonseca F; Langohr K; De La Torre R
Ann N Y Acad Sci; 2006 Aug; 1074():559-76. PubMed ID: 17105953
[TBL] [Abstract][Full Text] [Related]
2. Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users.
Abanades S; Farré M; Barral D; Torrens M; Closas N; Langohr K; Pastor A; de la Torre R
J Clin Psychopharmacol; 2007 Dec; 27(6):625-38. PubMed ID: 18004131
[TBL] [Abstract][Full Text] [Related]
3. Disposition of gamma-hydroxybutyric acid in conventional and nonconventional biologic fluids after single drug administration: issues in methodology and drug monitoring.
Abanades S; Farré M; Segura M; Pichini S; Pastor A; Pacifici R; Pellegrini M; de la Torre R
Ther Drug Monit; 2007 Feb; 29(1):64-70. PubMed ID: 17304152
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers.
Thai D; Dyer JE; Jacob P; Haller CA
Clin Pharmacol Ther; 2007 Feb; 81(2):178-84. PubMed ID: 17192771
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulating properties of gamma-hydroxybutyrate (GHB), flunitrazepam and ethanol in 'club drugs' users.
Pichini S; Farré M; Abanades S; Pacifici R; Zuccaro P; Langohr K; de la Torre R
Addict Biol; 2010 Jul; 15(3):336-45. PubMed ID: 20456291
[TBL] [Abstract][Full Text] [Related]
6. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.
Parasrampuria DA; Schoedel KA; Schuller R; Gu J; Ciccone P; Silber SA; Sellers EM
J Clin Pharmacol; 2007 Dec; 47(12):1476-88. PubMed ID: 17962423
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of γ-hydroxybutyrate in healthy subjects.
Liechti ME; Quednow BB; Liakoni E; Dornbierer D; von Rotz R; Gachet MS; Gertsch J; Seifritz E; Bosch OG
Br J Clin Pharmacol; 2016 May; 81(5):980-8. PubMed ID: 26659543
[TBL] [Abstract][Full Text] [Related]
8. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
Johnson MW; Suess PE; Griffiths RR
Arch Gen Psychiatry; 2006 Oct; 63(10):1149-57. PubMed ID: 17015817
[TBL] [Abstract][Full Text] [Related]
9. Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB.
Carter LP; Richards BD; Mintzer MZ; Griffiths RR
Neuropsychopharmacology; 2006 Nov; 31(11):2537-51. PubMed ID: 16880774
[TBL] [Abstract][Full Text] [Related]
10. Sedative and hypothermic effects of gamma-hydroxybutyrate (GHB) in rats alone and in combination with other drugs: assessment using biotelemetry.
van Nieuwenhuijzen PS; McGregor IS
Drug Alcohol Depend; 2009 Aug; 103(3):137-47. PubMed ID: 19446408
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.
Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J
Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544
[TBL] [Abstract][Full Text] [Related]
12. Use, function, and subjective experiences of gamma-hydroxybutyrate (GHB).
Sumnall HR; Woolfall K; Edwards S; Cole JC; Beynon CM
Drug Alcohol Depend; 2008 Jan; 92(1-3):286-90. PubMed ID: 17766059
[TBL] [Abstract][Full Text] [Related]
13. Profiling the subjective, psychomotor, and physiological effects of a hydrocodone/acetaminophen product in recreational drug users.
Zacny JP; Gutierrez S; Bolbolan SA
Drug Alcohol Depend; 2005 Jun; 78(3):243-52. PubMed ID: 15893155
[TBL] [Abstract][Full Text] [Related]
14. Gamma-hydroxybutyrate detoxification by titration and tapering.
de Jong CA; Kamal R; Dijkstra BA; de Haan HA
Eur Addict Res; 2012; 18(1):40-5. PubMed ID: 22142784
[TBL] [Abstract][Full Text] [Related]
15. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence.
Galloway GP; Frederick SL; Staggers FE; Gonzales M; Stalcup SA; Smith DE
Addiction; 1997 Jan; 92(1):89-96. PubMed ID: 9060200
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.
Lal R; Sukbuntherng J; Luo W; Chen D; Vu A; Tovera J; Cundy KC
Clin Ther; 2009 Aug; 31(8):1776-86. PubMed ID: 19808136
[TBL] [Abstract][Full Text] [Related]
17. [Gamma-hydroxybutyrate--an endogenous substance and a new central nervous system stimulant. Clinical aspects of acute poisoning].
Engelsen J; Christensen HR
Ugeskr Laeger; 1999 Dec; 161(50):6903-7. PubMed ID: 10643375
[TBL] [Abstract][Full Text] [Related]
18. Detection of gamma-hydroxybutyrate in striatal microdialysates following peripheral 1,4-butanediol administration in rats.
Kapadia R; Böhlke M; Maher TJ
Life Sci; 2007 Feb; 80(11):1046-50. PubMed ID: 17188717
[TBL] [Abstract][Full Text] [Related]
19. Gamma-hydroxybutyrate--a drug of abuse.
Drasbek KR; Christensen J; Jensen K
Acta Neurol Scand; 2006 Sep; 114(3):145-56. PubMed ID: 16911342
[TBL] [Abstract][Full Text] [Related]
20. GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome.
Busardò FP; Jones AW
Curr Neuropharmacol; 2015 Jan; 13(1):47-70. PubMed ID: 26074743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
